|
Match
|
Document |
Document Title |
|
|
6734185 |
Pyrrolo&lsqb 3,4-d&rsqb pyrimidines as corticotropin releasing factor (CRF) antagonists
Corticotropin releasing factor (CRF) antagonists of Formula (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of...
|
|
|
6720350 |
Therapeutic inhibitor of vascular smooth muscle cells
Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic...
|
|
|
6713504 |
Antifungal molecule 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate
The present invention relates to a novel antifungal molecule 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate of formula (I) from a plant Datura metel a process for isolation...
|
|
|
6680319 |
Isoxazolecarboxamide derivatives
The invention relates to novel N-(substituted phenyl)-N′-[ω-(3-substituted phenyl-4-isoxazolecarbonylamino)alkyl]piperazines, their N-oxides, and pharmaceutically acceptable salts thereof. The...
|
|
|
6680338 |
Hydroxamic and carboxylic acid derivatives
Compounds having therapeutic utility are of formula (I) B—X—(CH 2 ) n —CR 2 R 3 —CR 4 R 5 —COY (I) wherein n=0-1; X is S(O) 0-2 ; Y is OR 1 or NHOH; R 2 and R 4 are independently H...
|
|
|
6673787 |
Sulfonamide-containing indole compounds
The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to...
|
|
|
6667310 |
Substituted guanidine derivatives
The present application provides guanidine derivatives of the formula (I) wherein R 1 , R 2 , R 3 , A and Z are as defined herein.
|
|
|
6653321 |
Naphthylsulfonic acids and related compounds as glucose uptake agonists
Methods for treating conditions associated with hyperglycemia, especially Type II diabetes, with novel naphthylsulfonic acids and related compounds. These compounds, as single stereoisomers or...
|
|
|
6641800 |
Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane
Pressurized aerosol composition for administration by inhalation comprising a liquefied hydrofluoroalkane, a powdered medicament dispersed therein, and a suspending agent comprising a polymer...
|
|
|
6641810 |
Methods of using geldanamycin and FK506 to treat peripheral nerve damage
FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid...
|
|
|
6642262 |
Riluzole and alpha-tocopherol combination
The invention concerns a combination of alpha-tocopherol and riluzole or a pharmaceutically acceptable salt thereof and the use of said combination for treating amyotrophic lateral sclerosis.
|
|
|
6632840 |
Monoacyl-substituted guanidines, a process for their preparation, their use as a medicament or diagnostic aid, and pharmaceutical compositions containing them
Monoacyl-substituted guanidines of formula III, or a salt or acid thereof, and their use as medicine or diagnostic aid: in which X(2) is
|
|
|
6632841 |
Soluble compositions of triphenylethylene antiestrogens
Aqueous compositions of nonsteroidal triphenylethylene antiestrogens for pharmaceutical use comprising as a solubility enhancing agent a pharmaceutically acceptable mono- or dicarboxylic acid...
|
|
|
6632834 |
Compositions and methods for treating conditions responsive to estrogen
This invention relates to methods, pharmaceutical compositions and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions...
|
|
|
6630476 |
Pyrrolo &lsqb 3,4-d&rsqb pyrimidines as corticotropin releasing factor (CRF) antagonists
Corticotropin releasing factor (CRF) antagonists of Formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of...
|
|
|
6620843 |
Anticancer treatment using triptolide prodrugs
Water soluble triptolide prodrugs are used as anticancer agents, and are found to be more effective in vivo, at lower doses, in reducing tumor size than the widely used chemotherapeutic agents...
|
|
|
6620806 |
Methods and kits for improving vascular health
The present invention provides methods and kits for improving or maintaining vascular health, including preventing myocardial infarction or stroke; maintaining or improving vascular reactivity;...
|
|
|
6610705 |
Process for the preparation of diaryl naphthyl methanes
The invention relates to novel diaryl naphthyl methane compounds having general formula I as shown herein below, and said compounds useful in the treatment of esterogen related disease or syndrome,...
|
|
|
6608050 |
Lyophilizate of lipid complex of water insoluble porphyrins
The present invention relates to a pharmaceutically acceptable dosage form of water insoluble porphyrins, particularly metal containing porphyrins such as tin porphyrin, which can be complexed with...
|
|
|
6599920 |
Naphthalene compounds, intermediates, formulations, and methods
This invention relates to the field of pharmaceutical and organic chemistry and provides naphthalene compounds, intermediates, formulations, and methods.
|
|
|
6599924 |
2-hetaryl-3,4-dihydro-2H-pyrrole derivatives
The invention relates to novel 2-hetaryl-3,4-dihydro-2H-pyrrole derivatives of the formula (I) in which Hetaryl represents substituted heterocyclyls and Ar represents substituted phenyl, to a...
|
|
|
6593347 |
Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated...
|
|
|
6576645 |
Triphenylalkene derivatives and their use as selective estrogen receptor modulators
The invention provides novel selective estrogen receptor modulator compounds of the general formula: wherein R1 and R2, which are the same or different are a) H, halogen, OCH 3 , OH; or where...
|
|
|
6548533 |
Ureido substituted pyrrolidines
The invention is directed to physiologically active compounds of formula (I): wherein one of A 1 , A 2 and A 3 represents NR 2 and the others represent C(R 3 )(R 4 ); R 1 represents R 5 Z 1...
|
|
|
6545037 |
Benzenesulfonamide compounds
A compound of formula (I): which is useful as a TXA 2 and 5-HT 2 receptor and pharmaceutical compositions containing the same.
|
|
|
6541506 |
Antifungal enediynes
The invention features enediynes and methods for their production and use. The enediynes of the invention have the formula: wherein R 1 is a hydroxyl group or a moiety that can be replaced by a...
|
|
|
6541505 |
Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds
This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a...
|
|
|
6541475 |
α, β-unsaturated sulfones for treating proliferative disorders
α, β-Unsaturated sulfones of the following formulae are provided, which are useful as antiproliferative agents, including, for example, anticancer agents:
|
|
|
6534499 |
N-substituted-N′-substituted urea derivatives and the use thereof as TNF-α production inhibitory agents
N-Substituted-N′-substituted urea derivatives represented by the following formula, analogs thereof or pharmaceutically acceptable salts thereof are herein provided. These compounds show a TNF-α...
|
|
|
6534546 |
Aniline derivatives possessing an inhibitory effect of nitric oxide synthase
Compounds represented by the general formula (1): (where R 1 is SR 6 or NR 7 R 8 , where R 6 is typically an alkyl group having 1-6 carbon atoms, R 7 is a hydrogen atom, an alkyl group...
|
|
|
6528518 |
Treatment of depression with kappa receptor antagonists
The invention features the treatment of depression using kappa opioid receptor antagonists.
|
|
|
6525068 |
Hydronaphtalene compounds, prepared by a rhodium catalyzed ring opening reaction in the presence of phosphine ligand
The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes...
|
|
|
6525099 |
N-substituted sulfonamide derivatives
The present invention provides certain N-substituted sulfonamide derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of...
|
|
|
6511979 |
Methods for treating conditions modulated by lactosylceramide
The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a...
|
|
|
6512002 |
Methods of treatment for premature ejaculation in a male
This invention relates to methods and pharmaceutical compositions useful in the treatment of conditions that are responsive to the elevation of testosterone levels in the body and the use of...
|
|
|
6509356 |
1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity
A class of substituted benzylnaphthylene compounds of the structure where R 1 and R 2 are independently hydrogen, alkyl of one to six carbon atoms, acyl of two to six carbon atoms, or...
|
|
|
6509359 |
Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors
A compound having the formula: wherein all variables are as defined in the specification, for use as a neuramninidase inhibitor.
|
|
|
6500823 |
Unsaturated hydroximic acid derivatives as per abstract inhibitors
The object of the invention consists of novel unsaturated hydroximic acid derivatives, the process for their preparation and as active substance such as compounds containing pharmaceutical...
|
|
|
6495568 |
Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors
Compounds of formula (I): or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line...
|
|
|
6489119 |
Analgesic screening method and composition
Disclosed is a method of selecting analgesic agents based on their selective ability to block tetrodotoxin-insensitive sodium channels, particularly in comparison to blocking tetrodotoxin-sensitive...
|
|
|
6486178 |
Indane derivatives
The present invention provides medicines for treating cardiac insufficiency which contain as an active ingredient indane derivatives of formula (I) wherein R 1 represents hydrogen atom, nitro...
|
|
|
6476027 |
N-hydroxy 4-sulfonyl butanamide compounds
An N-hydroxy sulfonyl butanamide compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated N-hydroxy...
|
|
|
6472406 |
Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
The intention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase...
|
|
|
6469011 |
Benzenesulfonamide compounds useful as TXA2 and 5-HT2 receptor antagonists
Compound of formula (I): which is useful as a TXA 2 and 5-HT 2 receptor antagonist and pharmaceutical compositions containing the same.
|
|
|
6458826 |
Composition for repelling and deterring pests
The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known compounds of formula (I), as defined herein before....
|
|
|
6451817 |
Alpha-substituted-1-benzyl-napthyls
This invention relates to the fields of pharmaceutical and organic chemistry and provides novel 1-benzyl-naphthyls which are α-substituted with ether, thioether, amino, hydrazino, cyano or halo...
|
|
|
6444688 |
Compounds and compositions with nitrogen-containing non-basic side chains
The instant invention provides compounds of formula I wherein R 1 is OH, O—C(O)—(C 1 -C 6 alkyl), O—C(O)—O(C 1 -C 6 alkyl), O—C(O)—Ar, or O—C(O)—O—Ar; R 2 is H, OH, O(C 1...
|
|
|
6436999 |
Diacyl-substituted guanidines, a process for their preparation, their use as medicine or diagnostic aid, and medicine containing them
Diacyl-substituted guanidines of the formula I are described where X( 1 ) and X( 2 ) are as defined herein. The compounds are suitable for use as antiarrhythmic pharmaceuticals possessing a...
|
|
|
6436925 |
Substituted benzamides, their production and their use as cysteine protease inhibitors
Benzamides of the formula I and its tautomeric forms, possible enantiomeric and diastereomeric forms, E and Z forms, and possible physiologically tolerated salts, in which the variables have the...
|
|
|
6420364 |
Compound useful as reversible inhibitors of cysteine proteases
Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formulas (I), (II), (Ia) and (Ib) further defined herein. The compounds are useful for treating autoimmune...
|